2024-12-19 – Press Releases – www.prnewswire.com
Based on promising early clinical results from PeproMene Bio’s PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. Patients with relapsed/refractory follicular…